Phase III Trials Of Covid Drug Movfor Show Positive Results, Says Hetero

Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine. The results, presented as an Oral Abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12-16,
http://dlvr.it/SKLdtZ